The study is testing a new drug called ES502 for people with advanced pancreatic cancer. This drug is for patients with a specific genetic marker called RAS G12V and who have no other treatment options. The study will check the safety of the drug and find out the best dose that can be given without causing too many side effects.

The study uses something called a "3+3" design. This means the first group of participants will get a low dose of the drug, and if it's safe, the next group will get a higher dose. The goal is to find the safest and most effective dose. The study will also look at how well the drug works against the cancer and how it moves through the body.

• Participants must be 18 years or older and have a specific genetic marker.
• Women must use birth control during the study and for a year after.
• The study will last until the best dose is found, which may take some time.